{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:19:54Z","timestamp":1740143994269,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T00:00:00Z","timestamp":1529366400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s40256-018-0287-y","type":"journal-article","created":{"date-parts":[[2018,6,18]],"date-time":"2018-06-18T22:21:08Z","timestamp":1529360468000},"page":"441-455","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithromboembolic Strategies for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3907-7166","authenticated-orcid":false,"given":"Ayesha","family":"Ather","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Laliberte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent N.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Devabhakthuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Y.","family":"See","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,19]]},"reference":[{"issue":"10","key":"287_CR1","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","volume":"135","author":"EJ Benjamin","year":"2017","unstructured":"Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart disease and stroke statistics\u20142017 update: a report from the American Heart Association. Circulation. 2017;135(10):e146\u2013603. \n                    https:\/\/doi.org\/10.1161\/CIR.0000000000000485\n                    \n                  .","journal-title":"Circulation"},{"key":"287_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ijcard.2015.01.053","volume":"183","author":"S Bangalore","year":"2015","unstructured":"Bangalore S, Gupta N, Genereux P, Guo Y, Pancholy S, Feit F. Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials: insight from over 8.1 million percutaneous coronary interventions. Int J Cardiol. 2015;183:6\u201310. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2015.01.053\n                    \n                  .","journal-title":"Int J Cardiol"},{"issue":"10","key":"287_CR3","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016;68(10):1082\u2013115. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"287_CR4","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","volume":"372","author":"MP Bonaca","year":"2015","unstructured":"Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. New Engl J Med. 2015;372(19):1791\u2013800. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1500857\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"23","key":"287_CR5","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. New Engl J Med. 2014;371(23):2155\u201366. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1409312\n                    \n                  .","journal-title":"New Engl J Med"},{"key":"287_CR6","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ahj.2016.07.015","volume":"180","author":"S Sra","year":"2016","unstructured":"Sra S, Tan MK, Mehta SR, Fisher HN, Dery JP, Welsh RC, et al. Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: insights from the Canadian observational AntiPlatelet sTudy. Am Heart J. 2016;180:82\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2016.07.015\n                    \n                  .","journal-title":"Am Heart J"},{"issue":"25","key":"287_CR7","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. New Engl J Med. 2016;375(25):2423\u201334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1611594\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"9526","key":"287_CR8","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/s0140-6736(06)68845-4","volume":"367","author":"J Pogue","year":"2006","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators CS, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, Pfeffer M, Hohnloser S, Yusuf S. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903\u201312. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(06)68845-4\n                    \n                  .","journal-title":"Lancet"},{"issue":"8","key":"287_CR9","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","volume":"114","author":"JW Eikelboom","year":"2006","unstructured":"Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774\u201382. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.612812\n                    \n                  .","journal-title":"Circulation"},{"issue":"16","key":"287_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","volume":"170","author":"ML Hansen","year":"2010","unstructured":"Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433\u201341. \n                    https:\/\/doi.org\/10.1001\/archinternmed.2010.271\n                    \n                  .","journal-title":"Arch Intern Med"},{"issue":"9872","key":"287_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/s0140-6736(12)62177-1","volume":"381","author":"WJM Dewilde","year":"2013","unstructured":"Dewilde WJM, Oirbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107\u201315. \n                    https:\/\/doi.org\/10.1016\/s0140-6736(12)62177-1\n                    \n                  .","journal-title":"Lancet"},{"issue":"12","key":"287_CR12","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med. 2009;361(12):1139\u201351. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0905561\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"22","key":"287_CR13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2013;369(22):2093\u2013104. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1310907\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"11","key":"287_CR14","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med. 2011;365(11):981\u201392. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1107039\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"10","key":"287_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New Engl J Med. 2011;365(10):883\u201391. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1009638\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"20","key":"287_CR16","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1016\/j.jacc.2017.03.540","volume":"69","author":"LN Marzec","year":"2017","unstructured":"Marzec LN, Wang J, Shah ND, Chan PS, Ting HH, Gosch KL, et al. Influence of direct oral anticoagulants on rates of oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2017;69(20):2475\u201384. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2017.03.540\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"287_CR17","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736\u201347. \n                    https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.009449\n                    \n                  .","journal-title":"Circulation"},{"issue":"9025","key":"287_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0140-6736(96)01109-9","volume":"348","author":"G Palareti","year":"1996","unstructured":"Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D\u2019Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet (London, England). 1996;348(9025):423\u20138.","journal-title":"Lancet (London, England)"},{"issue":"4","key":"287_CR19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692\u20134. \n                    https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x\n                    \n                  .","journal-title":"J Thromb Haemost"},{"issue":"9","key":"287_CR20","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1592\/phco.28.9.1098","volume":"28","author":"AC Seto","year":"2008","unstructured":"Seto AC, Kenyon K, Wittkowsky AK. Discrepancies in identification of major bleeding events in patients taking warfarin. Pharmacotherapy. 2008;28(9):1098\u2013103. \n                    https:\/\/doi.org\/10.1592\/phco.28.9.1098\n                    \n                  .","journal-title":"Pharmacotherapy"},{"issue":"1","key":"287_CR21","doi-asserted-by":"publisher","first-page":"E12","DOI":"10.1002\/ccd.26234","volume":"88","author":"C Bavishi","year":"2016","unstructured":"Bavishi C, Koulova A, Bangalore S, Sawant A, Chatterjee S, Ather S, et al. Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: a meta-analysis of observational studies. Catheter Cardiovasc Interv. 2016;88(1):E12\u201322. \n                    https:\/\/doi.org\/10.1002\/ccd.26234\n                    \n                  .","journal-title":"Catheter Cardiovasc Interv"},{"issue":"6","key":"287_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.jacc.2015.05.062","volume":"66","author":"CN Hess","year":"2015","unstructured":"Hess CN, Peterson ED, Peng SA, de Lemos JA, Fosbol EL, Thomas L, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol. 2015;66(6):616\u201327. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2015.05.062\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"287_CR23","doi-asserted-by":"publisher","first-page":"e0147245","DOI":"10.1371\/journal.pone.0147245","volume":"11","author":"A Sambola","year":"2016","unstructured":"Sambola A, Mutuberria M, Garcia Del Blanco B, Alonso A, Barrabes JA, Bueno H, et al. Impact of triple therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary intervention. PloS One. 2016;11(1):e0147245. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0147245\n                    \n                  .","journal-title":"PloS One"},{"issue":"16","key":"287_CR24","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","volume":"65","author":"KA Fiedler","year":"2015","unstructured":"Fiedler KA, Maeng M, Mehilli J, Schulz-Schupke S, Byrne RA, Sibbing D, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619\u201329. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2015.02.050\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"287_CR25","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2007;357(20):2001\u201315. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0706482\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"11","key":"287_CR26","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New Engl J Med. 2009;361(11):1045\u201357. \n                    https:\/\/doi.org\/10.1056\/NEJMoa0904327\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"20","key":"287_CR27","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","volume":"61","author":"N Sarafoff","year":"2013","unstructured":"Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61(20):2060\u20136. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.02.036\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"287_CR28","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","volume":"135","author":"OO Braun","year":"2015","unstructured":"Braun OO, Bico B, Chaudhry U, Wagner H, Koul S, Tyden P, et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res. 2015;135(1):26\u201330. \n                    https:\/\/doi.org\/10.1016\/j.thromres.2014.10.016\n                    \n                  .","journal-title":"Thromb Res"},{"issue":"6","key":"287_CR29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1177\/1074248417698042","volume":"22","author":"NJ Verlinden","year":"2017","unstructured":"Verlinden NJ, Coons JC, Iasella CJ, Kane-Gill SL. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. J Cardiovasc Pharmacol Ther. 2017;22(6):546\u201351. \n                    https:\/\/doi.org\/10.1177\/1074248417698042\n                    \n                  .","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"1","key":"287_CR30","doi-asserted-by":"publisher","first-page":"57","DOI":"10.18553\/jmcp.2017.23.1.57","volume":"23","author":"K Kim","year":"2017","unstructured":"Kim K, Lee TA, Touchette DR, DiDomenico RJ, Ardati AK, Walton SM. Contemporary trends in oral antiplatelet agent use in patients treated with percutaneous coronary intervention for acute coronary syndrome. J Manag Care Spec Pharm. 2017;23(1):57\u201363. \n                    https:\/\/doi.org\/10.18553\/jmcp.2017.23.1.57\n                    \n                  .","journal-title":"J Manag Care Spec Pharm"},{"issue":"8","key":"287_CR31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1105819","volume":"365","author":"JH Alexander","year":"2011","unstructured":"Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. New Engl J Med. 2011;365(8):699\u2013708. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1105819\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"1","key":"287_CR32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa1112277","volume":"366","author":"JL Mega","year":"2012","unstructured":"Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. New Engl J Med. 2012;366(1):9\u201319. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1112277\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"22","key":"287_CR33","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","volume":"32","author":"J Oldgren","year":"2011","unstructured":"Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32(22):2781\u20139. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehr113\n                    \n                  .","journal-title":"Eur Heart J"},{"issue":"16","key":"287_CR34","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. New Engl J Med. 2017;377(16):1513\u201324. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1708454\n                    \n                  .","journal-title":"New Engl J Med"},{"issue":"6","key":"287_CR35","doi-asserted-by":"publisher","first-page":"1035-1041.e1","DOI":"10.1016\/j.ahj.2010.07.038","volume":"160","author":"Laura Mauri","year":"2010","unstructured":"Mauri L, Kereiakes DJ, Normand SL, Wiviott SD, Cohen DJ, Holmes DR et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010;160(6):1035\u201341, 41 e1. doi:\n                    https:\/\/doi.org\/10.1016\/j.ahj.2010.07.038\n                    \n                  .","journal-title":"American Heart Journal"},{"issue":"24","key":"287_CR36","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","volume":"64","author":"EA Amsterdam","year":"2014","unstructured":"Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139\u2013228. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2014.09.017\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"key":"287_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","author":"M Valgimigli","year":"2017","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2017. \n                    https:\/\/doi.org\/10.1093\/eurheartj\/ehx419\n                    \n                  .","journal-title":"Eur Heart J"},{"issue":"12","key":"287_CR38","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","volume":"5","author":"JT Brandt","year":"2007","unstructured":"Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5(12):2429\u201336. \n                    https:\/\/doi.org\/10.1111\/j.1538-7836.2007.02775.x\n                    \n                  .","journal-title":"J Thromb Haemost"},{"issue":"2","key":"287_CR39","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/clpt.2011.132","volume":"90","author":"SA Scott","year":"2011","unstructured":"Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90(2):328\u201332. \n                    https:\/\/doi.org\/10.1038\/clpt.2011.132\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"287_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1161\/CIRCINTERVENTIONS.111.967083","volume":"5","author":"T Palmerini","year":"2012","unstructured":"Palmerini T, Kirtane AJ, Serruys PW, Smits PC, Kedhi E, Kereiakes D, et al. Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials. Circ Cardiovasc Interv. 2012;5(3):357\u201364. \n                    https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.111.967083\n                    \n                  .","journal-title":"Circ Cardiovasc Interv"},{"issue":"11","key":"287_CR41","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","volume":"62","author":"M Lamberts","year":"2013","unstructured":"Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol. 2013;62(11):981\u20139. \n                    https:\/\/doi.org\/10.1016\/j.jacc.2013.05.029\n                    \n                  .","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"287_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.amjcard.2015.03.033","volume":"116","author":"MG Mennuni","year":"2015","unstructured":"Mennuni MG, Halperin JL, Bansilal S, Schoos MM, Theodoropoulos KN, Meelu OA, et al. Balancing the risk of bleeding and stroke in patients with atrial fibrillation after percutaneous coronary intervention (from the AVIATOR Registry). Am J Cardiol. 2015;116(1):37\u201342. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2015.03.033\n                    \n                  .","journal-title":"Am J Cardiol"},{"issue":"2","key":"287_CR43","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1253\/circj.CJ-15-0923","volume":"80","author":"A Sambola","year":"2016","unstructured":"Sambola A, Mutuberria M, Garcia Del Blanco B, Alonso A, Barrabes JA, Alfonso F, et al. Effects of triple therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention regarding thromboembolic risk stratification. Circ J. 2016;80(2):354\u201362. \n                    https:\/\/doi.org\/10.1253\/circj.CJ-15-0923\n                    \n                  .","journal-title":"Circ J"},{"issue":"10","key":"287_CR44","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1016\/j.amjcard.2012.01.353","volume":"109","author":"A Rubboli","year":"2012","unstructured":"Rubboli A, Magnavacchi P, Guastaroba P, Saia F, Vignali L, Giacometti P, et al. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). Am J Cardiol. 2012;109(10):1411\u20137. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2012.01.353\n                    \n                  .","journal-title":"Am J Cardiol"},{"issue":"6","key":"287_CR45","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.amjcard.2011.10.046","volume":"109","author":"E Nikolsky","year":"2012","unstructured":"Nikolsky E, Mehran R, Dangas GD, Yu J, Parise H, Xu K, et al. Outcomes of patients treated with triple antithrombotic therapy after primary percutaneous coronary intervention for ST-elevation myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction [HORIZONS-AMI] trial). Am J Cardiol. 2012;109(6):831\u20138. \n                    https:\/\/doi.org\/10.1016\/j.amjcard.2011.10.046\n                    \n                  .","journal-title":"Am J Cardiol"},{"issue":"2","key":"287_CR46","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11239-012-0790-y","volume":"35","author":"G Denas","year":"2013","unstructured":"Denas G, Padayattil Jose S, Gresele P, Erba N, Testa S, De Micheli V, et al. Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. J Thromb Thrombolysis. 2013;35(2):178\u201384. \n                    https:\/\/doi.org\/10.1007\/s11239-012-0790-y\n                    \n                  .","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"287_CR47","first-page":"563","volume":"26","author":"A Rubboli","year":"2014","unstructured":"Rubboli A, Saia F, Sciahbasi A, Bacchi-Reggiani ML, Steffanon L, Briguori C, et al. Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. J Invasive Cardiol. 2014;26(11):563\u20139.","journal-title":"J Invasive Cardiol"},{"issue":"14","key":"287_CR48","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.jcin.2015.08.018","volume":"8","author":"LR Jackson 2nd","year":"2015","unstructured":"Jackson LR 2nd, Ju C, Zettler M, Messenger JC, Cohen DJ, Stone GW, et al. Outcomes of patients with acute myocardial infarction undergoing percutaneous coronary intervention receiving an oral anticoagulant and dual antiplatelet therapy: a comparison of clopidogrel versus prasugrel from the TRANSLATE-ACS study. JACC Cardiovasc Interv. 2015;8(14):1880\u20139. \n                    https:\/\/doi.org\/10.1016\/j.jcin.2015.08.018\n                    \n                  .","journal-title":"JACC Cardiovasc Interv"},{"key":"287_CR49","unstructured":"Squibb B-M. A study of apixaban in patients with atrial fibrillation, not caused by a heart valve problem, who are at risk for thrombosis (blood clots) due to having had a recent coronary event, such as a heart attack or procedure to open the vessels of the hearts. Available from: \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02415400\n                    \n                  . NLM identifier: NCT02415400. Accessed 20 Oct 2017."},{"key":"287_CR50","unstructured":"Sankyo D. Edoxaban treatment versus vitamin K antagonist in patients with atrial fibrillation undergoing percutaneous coronary intervention (ENTRUST-AF-PCI). Available from:\u00a0\n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02866175\n                    \n                  . NLM identifier: NCT02866175. Accessed 20 Oct 2017."},{"key":"287_CR51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cct.2015.05.012","volume":"43","author":"F Gao","year":"2015","unstructured":"Gao F, Shen H, Wang ZJ, Yang SW, Liu XL, Zhou YJ.\u00a0Rationale and design of the RT-AF study: combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemp Clin Trials.\u00a02015;43:129\u201332. \n                    https:\/\/doi.org\/10.1016\/j.cct.2015.05.012\n                    \n                  .\u00a0","journal-title":"Contemp Clin Trials."},{"key":"287_CR52","unstructured":"Klinikum der Universitaet Muenchen. Apixaban vs. phenprocoumon in patients with ACS and AF: APPROACH-ACS-AF (APPROACH). Available from:\u00a0\n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02789917\n                    \n                  . NLM identifier: NCT02789917. Accessed 20 Oct 2017."},{"issue":"4","key":"287_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.ahj.2013.07.028","volume":"166","author":"A Sambola","year":"2013","unstructured":"Sambola A, Montoro JB, Del Blanco BG, Llavero N, Barrabes JA, Alfonso F, et al. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. Am Heart J. 2013;166(4):669\u201375. \n                    https:\/\/doi.org\/10.1016\/j.ahj.2013.07.028\n                    \n                  .","journal-title":"Am Heart J"},{"key":"287_CR54","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.cct.2014.12.002","volume":"40","author":"W Lu","year":"2015","unstructured":"Lu W, Chen L, Wang Y, Yao Y, Fu C, Zuo P, et al. Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. Contemp Clin Trials. 2015;40:166\u201371. \n                    https:\/\/doi.org\/10.1016\/j.cct.2014.12.002\n                    \n                  .","journal-title":"Contemp Clin Trials"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-0287-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0287-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T19:46:54Z","timestamp":1560887214000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-0287-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,19]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["287"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-0287-y","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"type":"print","value":"1175-3277"},{"type":"electronic","value":"1179-187X"}],"subject":[],"published":{"date-parts":[[2018,6,19]]},"assertion":[{"value":"19 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No external funding was used in the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"At the time of publication, Dr. Benjamin Laliberte is an employee of Novartis Pharmaceuticals Corporation. Ayesha Ather, Brent Reed, Kristin Watson, Sandeep Devabhakthuni, Ashley Schenk, and Vincent See have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}